Study finds long-term sustained effect of biological psoriasis treatment

June 28, 2017

Biological treatment of psoriasis shows a good efficacy in clinical trials. Since most analyses have focused on short-term outcomes of single biological agents, little has been known about long-term outcomes in clinical practice, where switching between biological agents is common. A Swedish study that followed 583 individuals for up to 10 years shows a satisfactory long-term effectiveness of biologic treatments. The findings were recently published in the British Journal of Dermatology.

"We employed a real-life patient perspective in this study," says Marcus Schmitt-Egenolf, professor at the Department of Public Health and Clinical Medicine at Umeå University and senior author of the study.

"Most studies in this area were initiated by the industry and conducted in controlled settings that are ultimately beneficial for their product. Consequently, those studies cannot really predict how a product will perform under real-life circumstances, with real-life patients."

The current study was based on data from repeated consultations of patients included in the Swedish psoriasis register and conducted by researchers at Umeå University and the Swedish Institute for Health Economics (IHE) in Lund.

Psoriasis is a common autoimmune skin disease affecting about three percent of the western population. Moderate-to-severe psoriasis is associated with a dose-dependent risk for cardiovascular and metabolic morbidity. In the beginning of the century, the introduction of a new class of drugs for psoriasis, biologics, transformed the treatment of moderate-to-severe psoriasis by providing better skin clearance rates, low toxicity, and improved quality-of-life. This study, following real-life patients for up to ten years, shows now that these good effects do not diminish over time.

In the study, researchers analysed three different measurements: the clinical measurement Psoriasis Area Severity Index (PASI), the DLQI which measures the impact of skin diseases on the quality of life, and the EQ-5D measurement, which analyses the general health-related quality of life.

"In all three of these measures of treatment outcome we found significant differences between before- and after the switch to biological treatment, both at 3-5 months after the switch and also sustained over the entire observed timespan," says Marcus Schmitt-Egenolf.

"Our results suggest that both the clinical effectiveness and the impressive effects on the quality of life under biological treatment as used in clinical practice are sustained over time. These results may support clinicians in initiating and continuing biological treatment for patients with poor outcomes under conventional treatment. This is an important finding from an international perspective, as data on real-life long-time outcomes of biological treatment is rare but crucial for treatment guidelines," concludes Marcus Schmitt-Egenolf.
About the article: The British Journal of Dermatology, article: Sustained PASI, DLQI and EQ-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register. Authors: F Hjalte, K Steen Carlsson and M. Schmitt-Egenolf. DOI: 10.1111/bjd.15757.

For more information, please contact:
Marcus Schmitt-Egenolf, Department of Public Health & Clinical Medicine, Dermatology unit, Umeå University
Phone: +46 (0)90 785 2875

Umea University

Related Psoriasis Articles from Brightsurf:

Most psoriasis patients taking immunosuppressants survive COVID-19
Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19.

Getting under the skin of psoriasis
Psoriasis afflicts millions of people worldwide, but treatments are limited to small molecules like steroids, which can cause skin thinning and lose their effectiveness over time.

Psoriasis patients' mental health is more than skin-deep
A new study from Umeå University, Sweden, shows that other somatic diseases have even more impact on patients' mental health than their skin symptoms, highlighting the importance of holistic patient care.

Psoriasis: Towards a novel therapeutic approach
Researchers at the Université libre de Bruxelles (ULB) and the Department of Dermatology of the Erasme hospital uncover the importance of VEGFA signaling in the epidermis to mediate psoriasis development.

Insights into psoriasis suggest a new treatment target
Investigators from Brigham and Women's Hospital and the Harvard Stem Cell Institute have uncovered a novel pathway that may explain why skin thickens in psoriasis and suggests new strategies for developing therapies for the condition.

Psoriasis onset determines if psoriatic arthritis patients develop arthritis or psoriasis first
In a new study presented at the 2019 ACR/ARP Annual Meeting, researchers found the age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis.

Study: Some biologic treatments for psoriasis may be safer for patients
In the largest study of its kind, Erica D. Dommasch, M.D., M.P.H., a dermatologist in the Department of Dermatology at BIDMC, and colleagues found a decreased risk of infection in patients with psoriasis using some of the newer, more targeted medications compared to those taking methotrexate, a drug widely used since the 1960s as a first line treatment for moderate-to-severe psoriasis.

Higher weight increases risk of psoriasis
The higher a person's BMI, the greater the chance of getting psoriasis.

Lipid that aids normal skin turnover may help psoriasis
Topical application of the lipid phosphatidylglycerol, or PG, on a mouse model of psoriasis reduced inflammation as well as characteristic, raised skin lesions, they report in the Journal of Investigative Dermatology.

New insight into the mechanism of the drug against sclerosis and psoriasis
A multidisciplinary research team at Aarhus University has provided fundamental new insight into the mechanism of the medical drug dimethyl fumarate, which is the active component of important treatments for multiple sclerosis and psoriasis.

Read More: Psoriasis News and Psoriasis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to